|
|
Murametide |
|
Vaxjo ID |
64 |
|
Vaccine Adjuvant Name |
Murametide |
|
Alternative Names |
Nac-Mur-L-Ala-D-Gln-OCH3 |
|
Adjuvant VO ID |
VO_0001303
|
|
Description |
Administered in water-in-oil (w/o) emulsion as adjuvant of humoral and cell-mediated immunity (Vogel and Powell, 1995). |
|
Stage of Development |
Clinical Trial |
|
Components |
Nac-Mur-L-Ala-D-Gln-OCH3 (Vogel and Powell, 1995). |
|
Molecular Weight |
506.5 |
|
Appearance |
White powder. |
|
Storage |
Stored as a powder at 4°C. Protect from light and humidity. Stable for more than 5 years (Vogel and Powell, 1995). |
|
Function |
When administered in saline, Murametide is non pyrogenic, induces granulocytosis and enhances the humoral response. Murametide displays the same profile of adjuvant activity as MDP and has been chosen for development because of its favorable therapeutic ratio. When administered in 50% water-in-oil emulsion, it mimics the activity of Freund's complete adjuvant without its side effects (Vogel and Powell, 1995). |
|
Safety |
Acute, subacute and chronic toxicity performed in rats and monkeys allow administration in clinical studies of 1 to 4 s.c. injections at 2-4 week intervals at doses of 35-100 μg/kg. Pharmacokinetics was performed in rats and dogs. A Phase I clinical trial was completed that showed no toxicity at dosages up to 150 μg/kg (Vogel and Powell, 1995). |
| References |
Vogel and Powell, 1995: Vogel FR, Powell MF. A compendium of vaccine adjuvants and excipients. Pharmaceutical biotechnology. 1995; 6; 141-228. [PubMed: 7551218].
|
|
